Longevity Health Holdings, Inc. (XAGE) Spending and interest coverage
- R&D / revenue · 12 months: Value 29.18%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 36.07%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 29.18% | Research and development expense / revenue. Period ending 2026-06-30. $492.21K ÷ $1.69M × 100 ≈ 29.18% |
| Stock-based compensation / revenue · 12 months | 36.07% | Share-based compensation / revenue. Period ending 2026-06-30. $608.32K ÷ $1.69M × 100 ≈ 36.07% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 492.21K USD | Research and Development Expense |
| Revenue | 1.69M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 608.32K USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -5.79M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $492.21K | $1.69M | $608.32K | $-5.79M | (m) | 29.18% | 36.07% | (m) | (m) |
| 2026-03-31 | $647.46K | $1.79M | $723.89K | $-6.93M | $16.67K | 36.09% | 40.35% | -415.65× | Reported |
| 2025-12-31 | $788.89K | $1.91M | $692.79K | $-7.11M | $18.21K | 41.24% | 36.22% | -390.23× | Reported |
| 2025-09-30 | $873.83K | $1.46M | $765.26K | $-5.84M | $20.11K | 59.96% | 52.51% | -290.62× | Reported |
| 2025-06-30 | $946.34K | $1.05M | $761.03K | $-5.79M | $22.17K | 89.96% | 72.34% | -261.25× | Reported |
| 2025-03-31 | $821.80K | $560.67K | $730.40K | $-5.12M | $22.87K | 146.57% | 130.27% | -224.06× | Reported |
| 2024-12-31 | $1.05M | $50.32K | $827.04K | $-5.00M | $29.45K | 2095.29% | 1643.63% | -169.75× | Reported |
| 2024-09-30 | $207.63K | (m) | $623.25K | $-4.32M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $1.47M | (m) | $675.31K | $-5.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $2.19M | (m) | $698.64K | $-6.05M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $2.50M | (m) | $667.68K | $-5.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | $-6.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | $-2.75M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | $-1.87M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $-1.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STEPAN CO (SCL) | United States | $1.451B | -477.05 |
| CHURCH & DWIGHT CO INC /DE/ (CHD) | United States | $22.622B | 30.81 |
| ECOLAB INC. (ECL) | United States | $77.183B | 36.58 |
| PROCTER & GAMBLE Co (PG) | United States | $338.763B | 21.26 |